Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

LLY - ELI LILLY & Co


813.48
11.830   1.454%

Share volume: 3,072,760
Last Updated: 03-14-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.19%

PREVIOUS CLOSE
CHG
CHG%

$801.65
11.83
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
81%
Profitability 100%
Dept financing 33%
Liquidity 57%
Performance 80%
Company vs Stock growth
vs
Performance
5 Days
-1.96%
1 Month
-5.10%
3 Months
4.43%
6 Months
-11.92%
1 Year
7.86%
2 Year
146.91%
Key data
Stock price
$813.48
P/E Ratio 
65.79
DAY RANGE
$800.00 - $815.21
EPS 
$11.76
52 WEEK RANGE
$711.40 - $972.53
52 WEEK CHANGE
$6.66
MARKET CAP 
696.733 B
YIELD 
0.67%
SHARES OUTSTANDING 
950.426 M
DIVIDEND
$1.50
EX-DIVIDEND DATE
02-14-2025
NEXT EARNINGS DATE
N/A
BETA 
0.81
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,826,741
AVERAGE 30 VOLUME 
$3,636,938
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax

Recent news